[{"id":"a0174285-3806-422a-a9e4-db7d8c284645","acronym":"YBL006C101","url":"https://clinicaltrials.gov/study/NCT04450901","created_at":"2021-01-18T21:24:47.261Z","updated_at":"2024-07-02T16:35:59.694Z","phase":"Phase 1/2","brief_title":"Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04450901 - YBL006C101","lead_sponsor":"Y Biologics Inc.","biomarkers":" EGFR • PD-L1 • ALK • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • ALK translocation","tags":["EGFR • PD-L1 • ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acrixolimab (YBL-006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2022-12-05"}]